Gilead Sciences Inc. (NASDAQ:GILD) – Gilead to seek okay for combo hepatitis C pill in Q1

December 18, 2013 at 11:21 AM EST

[Reuters] – Gilead Sciences Inc, based on favorable new clinical trial data, said it will seek U.S. approval in the first quarter of 2014 for a once-daily tablet containing two new treatments for . . . → Read More: Gilead Sciences Inc. (NASDAQ:GILD) – Gilead to seek okay for combo hepatitis C pill in Q1 Similar posts: Gilead Sciences Inc. (NASDAQ:GILD) – New Hepatitis C Drug Success Should Drive Gilead Sciences In 2014 AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review

Gilead Sciences Inc. (NASDAQ:GILD) [Reuters] – Gilead Sciences Inc, based on favorable new clinical trial data, said it will seek U.S. approval in the first quarter of 2014 for a once-daily tablet containing two new treatments for hepatitis C. The …
Read more on this.

Gilead Sciences Inc. (GILD), currently valued … [visit site to read more]